DRUG-RELATED PROBLEMS IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA CANCER

Acute lymphoblastic leukemia that occurs in children is about 75% - 80%. The main treatment of acute lymphoblastic leukemia in children involves the use of chemotherapy with complex regimens and higher doses. Complex drug therapy causes a high risk of drug-related problems (DRPs). The purpose of this study was to determine the percentage of DRPs, identify the types of DRPs, and evaluate the correlation between age, gender, comorbidities, and the number of drugs with the incidence of DRPs in pediatric patients with acute lymphoblastic leukemia in Dr. Kariadi Hospital and Dr. Moewardi Hospital in the period July - October 2019. This study is an evaluative descriptive study with prospective data collection. The inclusion criteria in this study were patients diagnosed with acute lymphoblastic leukemia, patients aged 0-<18 years, and patients undergoing inpatient treatment or one-day care. Data were then analyzed using SPSS, namely Chi-Square. The use of chemotherapy regimens in this study was based on the hospital's acute lymphoblastic leukemia treatment protocol—identification of DRPs based on PCNE V8.02 2017. DRPs found in pediatric patients with acute lymphoblastic leukemia are the safety of therapy category adverse drug reactions (P2.1) 36.36% (36 patients). The results of the Chi-Square analysis showed no association between the risk factors of age, gender, comorbidities, and the number of drugs with the incidence of DRPs (P>0.05).